The stock's fall snapped a two-day winning streak.

2024 was one of the most eventful years for the pharmaceutical, biotech, life sciences and medical marketing industries.

In this deep dive BioSpace explores the opportunities and challenges presented by the FDA’s accelerated approval program.

Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV ...

Trump has regularly promoted suspicion about vaccines causing autism going back to before he ran for president in 2015. In ...

Trump touched off a frenzy over RFK Jr. and vaccines — one reporter asked "What about the polio vaccine?" and Trump responded "everything should be looked at." ...

Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by ...

CHARLESTON, W.Va. — West Virginia Attorney General Patrick Morrisey on Thursday said the Circuit Court of Mason County has approved a settlement between the state and pharmaceutical companies Pfizer ...

As of the latest trading close, PFE, a Healthcare sector stock, is trading -18.90% below its 52-week high but remains 4.49% above its 52-week low. The Average True Range (ATR) (14 days) of 0.55 ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...